Reimagining Medicine slide image

Reimagining Medicine

Company overview Financial review 2023 priorities Appendix Harry Kirsch Chief Financial Officer Financial review and 2023 guidance 34 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation